The pan-HDAC inhibitor panobinostat and the class I HDAC-specific inhibitor entinostat (MS-275) dose-dependently upregulated PD-L1 expression by MM cells (Figure 2A). Here, HDAC9 is linked to Miyoshi myopathy.